PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
Completed
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00163618
- Locations
- 🇦🇹
Freistädter Strasse 290, Linz, Austria
🇦🇹Bahnhofstraße 9, Hermagor, Austria
🇦🇹Conrad-von-Hoetzendorf-Strasse, Voitsberg, Austria
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
Phase 4
Completed
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00163540
- Locations
- 🇧🇪
SGS Biopharma Research Unit Stuivenberg, Antwerp, Belgium
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 98
- Registration Number
- NCT00163189
- Locations
- 🇫🇷
Centre de Perharidy, Roscoff Cedex, France
🇫🇷Hôpital Lenval, Nice, France
🇫🇷CHU Timone Enfants, Marseille Cedex 5, France
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
Phase 4
Completed
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00161954
- Locations
- 🇧🇪
SGS Biopharma Research Unit Stuivenberg, Antwerp, Belgium
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
Phase 3
Completed
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3973
- Registration Number
- NCT00161876
- Locations
- 🇵🇱
Zespol Opieki Zdrowotnej w Debicy, Debica, Poland
🇵🇱PANTAMED sp. z o.o., Olsztyn, Poland
🇵🇱Przedsiebiorstwo Uslug Medycznych "Centrum Medyczne Nowa Huta", Krakow, Poland
Growth Retardation In Children With Special Pathological Conditions Or Disease
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00163215
- Locations
- 🇫🇷
Pfizer Investigational Site, Vandoeuvre Les Nancy Cedex, France
A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
Phase 3
Completed
- Conditions
- Candidiasis
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 412
- Registration Number
- NCT00163111
A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 136
- Registration Number
- NCT00163098
- Locations
Pfizer Investigational Site
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
Phase 2
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-09-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00163085
- Locations
- 🇺🇸
Pfizer Investigational Site, Portland, Oregon, United States
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
Phase 2
Completed
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-09-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00163059
- Locations
- 🇺🇸
Pfizer Investigational Site, Wichita, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath